 |
| This is Page 16 |
| Cari Loder's Treatment. This is the last contact I had on the 7 th June 1999. A letter from Scotia Pharmaceuticals, the company undertaking Cari's treatment. |
| SCOTIA Scotia Pharmaceuticals Limited Scotia House Castle Business Park STIRLING 7 June 1999 Scotland Mr Philip Spencer Dear Mr Spencer [hank you for your recent enquiry regarding the outcome of our clinical trial based on the Cari Loder treatment. The study ran in five centres. One hundred and thirty-eight patients were studied: 69 had active triple therapy and 69 were controls. A first analysis of the data has been completed. The study did not find any overall difference in disability at 24 weeks between patients given active treatment and patients who only received vitamin 812 injections, in both groups there was a slight improvement over the first two weeks. More detailed analysis suggests that patients with the active treatment might suffer slightly fewer MS symptoms, but they also suffered more (expected) side-effects attributable to the drugs under study. [his study cannot currently support the routine use of this combination therapy for people who have multiple sclerosis. 11w study will be written up and published in a medical journal. There will be some further analysis to see if any specific group of patients may benefit. In the meantime we cannot recommend this treatment. If you feel you have benefited or are still benefiting then it seems safe and reasonable to continue as the side-effects were not dangerous. You should discuss this with your OP or neurologist if you have any concerns or questions. Kind regards. Yours sincerely Karen McGregor Clinical Research Associate |
|
 |
 |
|
|
|